See more : Skillsoft Corp. (SKIL-WT) Income Statement Analysis – Financial Results
Complete financial analysis of GT Biopharma, Inc. (GTBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GT Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Zepp Health Corporation (ZEPP) Income Statement Analysis – Financial Results
- Autohellas S.A. (AOHLF) Income Statement Analysis – Financial Results
- Cohn Robbins Holdings Corp. (CRHWF) Income Statement Analysis – Financial Results
- Daiki Aluminium Industry Co., Ltd. (5702.T) Income Statement Analysis – Financial Results
- Prudential Bancorp, Inc. (PBIP) Income Statement Analysis – Financial Results
GT Biopharma, Inc. (GTBP)
About GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 | 1984 | 1983 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.00K | 61.00K | 368.00K | 342.00K | 26.00K | 11.00K | 48.00K | 1.14M | 6.05M | 5.78M | 2.50M | 2.36M | 2.74M | 2.05M | 2.97M | 3.54M | 7.17M | 5.10M | 5.10M | 4.90M | 5.10M | 3.50M | 3.00M | 2.80M | 2.70M | 4.80M | 5.10M | 3.20M | 2.30M | 3.00M | 2.40M | 4.16M | 3.83M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 7.00K | 2.00K | 1.00K | 2.00K | 57.00K | 226.00K | 94.00K | 48.00K | 65.00K | 50.00K | 909.00K | 3.26M | 3.08M | 1.35M | 1.22M | 1.50M | 1.14M | 2.43M | 2.62M | 5.05M | 2.60M | 2.00M | 1.60M | 1.60M | 1.50M | 1.20M | 1.20M | 1.00M | 1.90M | 2.10M | 1.20M | 500.00K | 1.10M | 900.00K | 2.33M | 2.28M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -4.00K | -7.00K | -2.00K | -1.00K | 25.00K | 4.00K | 142.00K | 248.00K | -22.00K | -54.00K | -2.00K | 234.00K | 2.79M | 2.69M | 1.15M | 1.15M | 1.24M | 910.00K | 538.00K | 924.00K | 2.11M | 2.50M | 3.10M | 3.30M | 3.50M | 2.00M | 1.80M | 1.60M | 1.70M | 2.90M | 3.00M | 2.00M | 1.80M | 1.90M | 1.50M | 1.83M | 1.55M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 92.59% | 6.56% | 38.59% | 72.51% | -84.62% | -490.91% | -4.17% | 20.47% | 46.09% | 46.61% | 46.14% | 48.56% | 45.40% | 44.39% | 18.13% | 26.10% | 29.50% | 49.02% | 60.78% | 67.35% | 68.63% | 57.14% | 60.00% | 57.14% | 62.96% | 60.42% | 58.82% | 62.50% | 78.26% | 63.33% | 62.50% | 43.99% | 40.47% |
| Research & Development | 6.47M | 8.81M | 9.59M | 485.00K | 1.67M | 9.07M | 1.07M | 975.00K | 1.00M | 0.00 | 0.00 | 0.00 | 17.00K | 179.00K | 0.00 | 44.00K | 1.04M | 708.00K | 499.00K | 236.00K | 369.00K | 463.00K | 762.00K | 1.91M | 2.40M | 4.40M | 4.30M | 4.90M | 4.30M | 1.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 590.00K | 400.00K |
| General & Administrative | 0.00 | 0.00 | 47.92M | 6.28M | 9.79M | 12.49M | 0.00 | 0.00 | 0.00 | 0.00 | 935.00K | 3.36M | 3.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.13M | 1.19M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 400.00K | 420.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.11M | 12.45M | 47.92M | 6.28M | 9.79M | 12.49M | 134.50M | 8.40M | 7.95M | 2.40M | 935.00K | 3.76M | 3.89M | 2.26M | 1.15M | 1.40M | 2.87M | 4.65M | 2.34M | 2.03M | 1.65M | 1.26M | 2.29M | 3.30M | 3.29M | 3.60M | 2.60M | 2.80M | 3.30M | 1.70M | 3.40M | 2.10M | 2.20M | 2.40M | 2.50M | 2.10M | 1.60M | 2.50M | 2.30M | 1.13M | 1.19M |
| Other Expenses | 0.00 | 0.00 | -242.76K | -12.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 155.00K | 0.00 | 0.00 | 0.00 | 942.00K | 443.00K | 838.00K | 1.60M | 1.20M | 1.40M | 1.40M | 600.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K |
| Operating Expenses | 13.58M | 21.26M | 57.52M | 6.76M | 11.46M | 21.55M | 135.57M | 9.37M | 8.95M | 2.40M | 935.00K | 3.76M | 3.91M | 2.44M | 1.15M | 1.45M | 3.90M | 5.36M | 2.84M | 2.26M | 2.02M | 1.72M | 3.99M | 5.65M | 6.52M | 9.60M | 8.10M | 9.10M | 9.00M | 4.00M | 3.50M | 2.10M | 2.20M | 2.40M | 2.50M | 2.10M | 1.60M | 2.50M | 2.30M | 1.72M | 1.60M |
| Cost & Expenses | 13.58M | 21.26M | 57.52M | 6.76M | 11.46M | 21.55M | 135.57M | 9.37M | 8.95M | 2.46M | 1.16M | 3.86M | 3.95M | 2.51M | 1.20M | 2.35M | 7.17M | 8.45M | 4.19M | 3.48M | 3.51M | 2.86M | 6.42M | 8.27M | 11.58M | 12.20M | 10.10M | 10.70M | 10.60M | 5.50M | 4.70M | 3.30M | 3.20M | 4.30M | 4.60M | 3.30M | 2.10M | 3.60M | 3.20M | 4.05M | 3.88M |
| Interest Income | 567.00K | 292.00K | 38.00K | 3.32K | 2.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 0.00 | 52.00K | 80.00K | 110.00K | 1.00K | 1.00K | 7.00K | 29.00K | 180.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 8.00K | 718.00K | 3.32M | 2.13M | 9.12M | 8.60M | 6.56M | 17.04M | 5.15M | 1.20M | 1.65M | 556.00K | 513.00K | 1.14M | 1.66M | 1.01M | 2.16M | 26.00K | 101.00K | 14.00K | 18.00K | 14.00K | 90.00K | 0.00 | 300.00K | 0.00 | 100.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 290.00K | 210.00K |
| Depreciation & Amortization | 13.58M | 21.26M | 57.52M | 4.00K | 4.00K | 7.00K | 2.00K | 1.00K | 2.00K | 22.00K | 2.00K | 3.00K | 23.00K | 31.00K | 55.00K | 251.00K | 893.00K | 301.00K | 154.00K | 785.00K | 177.00K | 282.00K | 412.00K | 443.00K | 838.00K | 1.60M | 1.20M | 1.40M | 1.40M | 600.00K | 100.00K | -300.00K | -300.00K | -300.00K | -300.00K | -200.00K | 100.00K | -200.00K | -300.00K | 790.00K | 480.00K |
| EBITDA | 5.98M | 0.00 | 0.00 | -24.98M | -11.45M | -250.06M | -135.57M | -9.37M | -8.93M | -2.37M | -791.00K | -3.61M | -3.12M | -2.45M | -1.06M | -822.00K | -223.00K | -2.37M | -1.54M | -1.72M | -596.00K | -529.00K | -3.04M | -4.28M | -3.57M | -5.50M | -3.80M | -4.50M | -4.10M | -1.40M | -1.60M | -800.00K | -800.00K | 200.00K | 200.00K | -300.00K | 200.00K | -800.00K | -1.10M | 890.00K | 430.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33,055.56% | -3,891.80% | -602.17% | -1,026.61% | -15,019.23% | -22,418.18% | -2,285.42% | -83.99% | -48.64% | -42.64% | -1.56% | 47.08% | -22.04% | -25.80% | -68.80% | -120.99% | -50.65% | -113.73% | -76.47% | -89.80% | -15.69% | 62.86% | -60.00% | -28.57% | -29.63% | 4.17% | 3.92% | -9.38% | 13.04% | -26.67% | -45.83% | 21.39% | 11.23% |
| Operating Income | -13.58M | -21.26M | -57.52M | -6.76M | -16.06M | -250.07M | -135.57M | -9.37M | -8.93M | -2.40M | -793.00K | -3.51M | -3.93M | -2.50M | -1.16M | -1.21M | -1.12M | -2.67M | -3.19M | -1.72M | -773.00K | -811.00K | -3.45M | -4.73M | -4.41M | -7.10M | -5.00M | -5.80M | -5.50M | -2.00M | -1.70M | -500.00K | -500.00K | 500.00K | 500.00K | -100.00K | 200.00K | -600.00K | -800.00K | 100.00K | -50.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33,062.96% | -3,927.87% | -215.49% | -1,027.49% | -15,107.69% | -22,700.00% | -2,408.33% | -105.95% | -18.45% | -46.23% | -127.71% | -72.72% | -28.21% | -39.56% | -116.34% | -133.50% | -61.55% | -139.22% | -98.04% | -118.37% | -107.84% | -57.14% | -56.67% | -17.86% | -18.52% | 10.42% | 9.80% | -3.13% | 8.70% | -20.00% | -33.33% | 2.40% | -1.31% |
| Total Other Income/Expenses | 5.98M | 373.00K | -498.00K | -21.53M | -22.59M | -9.12M | -7.68M | 19.14M | -12.53M | -21.11M | 229.00K | -1.75M | 228.00K | -498.00K | -1.09M | -1.50M | 1.49M | -1.98M | 82.00K | -937.00K | -5.00K | -11.00K | -999.00K | 0.00 | 57.00K | 300.00K | 100.00K | 0.00 | -3.30M | -3.60M | 200.00K | 300.00K | 300.00K | 300.00K | 300.00K | 200.00K | 200.00K | 200.00K | 300.00K | 290.00K | 210.00K |
| Income Before Tax | -7.60M | -20.88M | -58.01M | -28.30M | -38.65M | -259.19M | -143.25M | 21.03M | -32.73M | -23.49M | -564.00K | -5.26M | -3.70M | -3.00M | -2.25M | -2.71M | 546.00K | 4.82M | -3.11M | -2.66M | -778.00K | -822.00K | -4.45M | 0.00 | -4.35M | -6.80M | -4.90M | 0.00 | -8.80M | -5.60M | -1.50M | -200.00K | -200.00K | 800.00K | 800.00K | 100.00K | 400.00K | -400.00K | -500.00K | 390.00K | 160.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -121,207.41% | -38,506.56% | -153.26% | -1,538.30% | -14,230.77% | -27,227.27% | -4,679.17% | -237.01% | 9.03% | 83.45% | -124.43% | -112.35% | -28.39% | -40.10% | -150.00% | 0.00% | -60.75% | -133.33% | -96.08% | 0.00% | -172.55% | -160.00% | -50.00% | -7.14% | -7.41% | 16.67% | 15.69% | 3.13% | 17.39% | -13.33% | -20.83% | 9.38% | 4.18% |
| Income Tax Expense | 0.00 | -381.00K | 680.00K | 3.32M | 2.13M | -228.52M | 7.68M | -30.41M | 17.04M | 5.15M | -292.00K | 1.56M | 556.00K | 513.00K | 1.14M | 77.00K | 75.00K | 120.00K | 2.00K | 1.54M | 13.00K | 0.00 | 42.00K | -42.00K | 85.00K | 0.00 | 200.00K | 200.00K | 3.40M | 3.60M | -200.00K | 100.00K | 0.00 | -100.00K | 100.00K | 0.00 | 100.00K | 0.00 | -200.00K | 180.00K | 70.00K |
| Net Income | -7.60M | -20.50M | -58.69M | -31.62M | -40.78M | -259.19M | -143.25M | 21.03M | -32.73M | -23.49M | -501.00K | -5.17M | -3.70M | -3.00M | -2.25M | -5.01M | 471.00K | -4.94M | -3.11M | -2.66M | -791.00K | -822.00K | -3.50M | -4.68M | -4.50M | -7.10M | -5.20M | -6.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 900.00K | 700.00K | 100.00K | 300.00K | -400.00K | -300.00K | 420.00K | 150.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -121,207.41% | -38,506.56% | -136.14% | -1,511.99% | -14,230.77% | -27,227.27% | -4,679.17% | -437.97% | 7.79% | -85.53% | -124.51% | -112.35% | -28.87% | -40.10% | -117.76% | -132.32% | -62.74% | -139.22% | -101.96% | -122.45% | -174.51% | -160.00% | -50.00% | -10.71% | -7.41% | 18.75% | 13.73% | 3.13% | 13.04% | -13.33% | -12.50% | 10.10% | 3.92% |
| EPS | -5.64 | -19.30 | -62.54 | -216.29 | -361.49 | -87.70 | -145.22 | 4.39K | -69.63K | -50.62K | -1.12K | -13.19K | -17.54K | -25.60K | -43.19K | -139.06K | 13.08K | -145.29K | -94.21K | -83.00K | -39.55K | -117.43K | -499.29K | -669.14K | -749.17K | -1.18M | -1.30M | -3.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 1.08M | 956.34K | 191.27K | 382.54K | -400.00K | -300.00K | 0.01 | 0.00 |
| EPS Diluted | -5.64 | -19.30 | -62.54 | -216.29 | -361.49 | -87.70 | -145.22 | 4.39K | -69.63K | -50.62K | -1.12K | -13.19K | -17.54K | -25.60K | -43.19K | -139.06K | 13.08K | -145.29K | -94.21K | -83.00K | -39.55K | -117.43K | -499.29K | -669.14K | -749.17K | -1.18M | -1.30M | -3.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 1.08M | 956.34K | 191.27K | 382.54K | -400.00K | -300.00K | 0.01 | 0.00 |
| Weighted Avg Shares Out | 1.35M | 1.06M | 938.52K | 146.17K | 112.80K | 2.96M | 986.42K | 4.79K | 470.00 | 464.00 | 449.00 | 392.00 | 211.00 | 117.00 | 52.00 | 36.00 | 36.00 | 34.00 | 33.00 | 32.00 | 20.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 30.58M | 30.58M |
| Weighted Avg Shares Out (Dil) | 1.35M | 1.06M | 938.52K | 146.17K | 112.80K | 2.96M | 986.42K | 4.79K | 470.00 | 464.00 | 449.00 | 392.00 | 211.00 | 117.00 | 52.00 | 36.00 | 36.00 | 34.00 | 33.00 | 32.00 | 20.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 30.58M | 30.58M |
GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical Officer
BEVERLY HILLS, Calif., Aug. 23, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® protein biologic technology platform, today announced...
GT Biopharma, Inc. (GTBP) CEO Tony Cataldo on Q2 2021 Results - Earnings Call Transcript
GT Biopharma, Inc. (GTBP) CEO Tony Cataldo on Q2 2021 Results - Earnings Call Transcript
GT Biopharma Provides Second Quarter 2021 Business Update
BEVERLY HILLS, Calif., Aug. 13, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE®) protein...
Former Penny Stocks To Watch After Merck's (MRK) Latest FDA Win
Merck's FDA and coronavirus vaccine news sparked momentum in biotech stocks today. Here are 4 to watch.
Hot Biotech Stocks That Deserve Your Attention In August 2021
Is it time to add biotech stocks to your list this year? The post Hot Biotech Stocks That Deserve Your Attention In August 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Are Penny Stocks Worth It? 5 That Deserve Your Attention Now
Have penny stocks presented some of the biggest opportunities in the stock market? The post Are Penny Stocks Worth It?
GTBP Stock Price Increases Over 6% Pre-Market: Why It Happened
The stock price of GT Biopharma, Inc. (NASDAQ: GTBP) increased by over 6% pre-market. This is why it happened.
Former Biotech Penny Stocks Seeing Explosive Moves In 2021
Are penny stocks worth it? Take a look at these 3 seeing explosive moves this year.
3 Biotech Penny Stocks To Watch On Robinhood IPO Day
These Former Penny Stocks Are Turning Heads Ahead Of Robinhood IPO The post 3 Biotech Penny Stocks To Watch On Robinhood IPO Day appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120%
Former penny stocks biotech analysts are bullish on right now. The post 3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports